Abstract
ABSTRACT Purpose Neuropathic pain frequently occurs in cancer patients, but the mechanism has yet to be clarified and no drug therapy has been established. The purpose of this study was to investigate the effect of duloxetine on neuropathic pain in cancer patients. Methods The subjects were 15 cancer patients (9 males) with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital between April 2011 and October 2011 and met the IASP diagnostic criteria for neuropathic pain. Duloxetine was administered in patients in whom pregabalin could not be administered, was ineffective, or was effective but the dose could not be elevated due to an adverse effect. The influence of duloxetine on pain and adverse effects was investigated retrospectively. Results Pain was reduced in 7 of the 15 patients. Sleepiness and a light-headed feeling were improved in three in whom pain was not reduced. Thus, the duloxetine was judged to be effective in 10 patients. The maintenance dose of duloxetine was 20–40 mg/day in patients who took the drug for 2 weeks or longer. Conclusion Duloxetine administration may be effective for neuropathic pain in cancer patients who cannot tolerate pregabalin administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
More From: Annals of Oncology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.